微波消融术前阿霉素磁液靶向化疗治疗原发性肝癌患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.02.032

摘要/Abstract

摘要： 目的研究微波消融术(MWA)前给予阿霉素磁液靶向化疗治疗原发性肝癌(PLC)患者的疗效及其血清肿瘤标记物的变化。方法 2018年1月～2021年1月我院诊治的PLC患者65例,采用随机数字表法将患者分为对照组32例和观察组33例,分别给予经皮MWA治疗或在MWA治疗前,采用Seldinger法插管至肿瘤供血动脉,给予阿霉素磁液靶向化疗。采用ELISA法检测血清糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、岩藻糖苷酶(AFU)和甲胎蛋白(AFP)水平,使用流式细胞仪检测外周血CD3⁺、CD4⁺和CD8⁺细胞百分比,并计算CD4⁺/CD8⁺细胞比值。结果观察组治疗总有效率为87.9%,显著高于对照组的65.6%(P＜0.05);在术后1 m,观察组血清CA19-9、CEA、AFU和AFP水平分别为(23.5±4.7)U/L、(9.3±2.1)μg/mL、(36.4±6.9)U/L和(78.5±10.2)ng/mL,显著低于对照组【分别为(31.2±5.1)U/L、(12.6±3.5)μg/mL、(45.1±10.2)U/L和(103.6±17.1)ng/mL,P＜0.05】;观察组外周血CD3⁺和CD4⁺细胞百分比及CD4⁺/CD8⁺细胞比值分别为(70.5±9.1)%、(39.8±4.7)%和(1.6±0.2),显著高于对照组【分别为(61.1±8.8)%、(31.9±4.4)%和(1.4±0.1),P＜0.05】。结论在采用MWA治疗PLC患者前应用阿霉素磁液靶向化疗有助于提高近期疗效,可能与改善了细胞免疫功能紊乱有关。

关键词: 原发性肝癌, 磁导向载体, 阿霉素, 微波消融, 治疗

Abstract: Objective The aim of this clinical trial was to investigate the preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation (MWA) in the treatment of patients with primary liver cancer (PLC). Methods 65 patients with PLC were encountered in our hospital between January 2018 and January 2021, and were randomly divided into observation (n=33) and control group (n=32). The patients in the control group was treated with percutaneous MWA, and those in the observation group was treated with preoperative doxorubicin magnetic fluid targeted chemotherapy before MWA. The clinical efficacy was evaluated by mRECIST. Serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), fucosidase (AFU) and alpha-fetoprotein (AFP) levels were detected by ELISA. The percentages of peripheral blood of CD3⁺, CD4⁺ and CD8⁺ cells were detected by flow cytometry. Results The total effective rate in the observation group at one-month evaluation was 87.9%, much higher than 65.6%(P＜0.05) in the control; at the end of one month after MWA, serum CA19-9, CEA, AFU and AFP levels in the observation group were (23.5±4.7)U/L,(9.3±2.1)μg/mL, (36.4±6.9)U/L and (78.5±10.2)ng/mL, all significantly lower than [(31.2±5.1)U/L, (12.6±3.5)μg/mL,(45.1±10.2)U/L and (103.6±17.1)ng/mL, respectively, P＜0.05] in the control; the percentages of peripheral blood CD3⁺ and CD4⁺ cells as well as the ratio of CD4⁺/CD8⁺ cells in the observation group were (70.5±9.1)%, (39.8±4.7)% and (1.6±0.2), all significantly higher than [(61.1±8.8)%, (31.9±4.4)% and (1.4±0.1), respectively, P＜0.05] in the control. Conclusion The procedure of adriamycin magnetic fluid targeted chemotherapy before MWA in dealing with patients with PLC could promote the short-term efficacy, which might be related to the regulation of immune functions.

Key words: Hepatoma, Magnetic guide carrier, Adriamycin, Microwave ablation, Therapy

史浩, 陈勇, 罗斌, 李道明. 微波消融术前阿霉素磁液靶向化疗治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 278-281.

Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.

参考文献

[1] Zhang L, Wang S, Yang Z, et al. An aptamer-nanotrain assembled from six-letter DNA delivers doxorubicin selectively to liver cancer cells. Angew Chem Int Ed Engl, 2020, 59(2): 663-668.
[2] Chen Y, Cheng L, Yu D, et al. Preparation of epidermal growth factor-modified targeted doxorubicin nanoliposomes and therapy of liver cancer. J Nanosci Nanotechnol, 2021, 21(9): 4565-4572.
[3] Liang B, Zhao D, Liu Y, et al. Chemoembolization of liver cancer with doxorubicin-loaded callispheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model. Drug Deliv Transl Res, 2020, 10(1): 185-191.
[4] Kang YJ, Lee BC, Kim JK, et al. Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating barcelona clinic liver cancer stage 0/a hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2020, 43(1): 55-64.
[5] Xu SY, Su H, Zhu XY, et al. Long-circulating doxorubicin and schizandrin a liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. J Liposome Res, 2022, 32(2): 107-118.
[6] Zong J, Peng H, Qing X, et al. pH-responsive pluronic f127-lenvatinib-encapsulated halogenated boron-dipyrromethene nanoparticles for combined photodynamic therapy and chemotherapy of liver cancer. ACS Omega, 2021, 6(18): 12331-12342.
[7] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 中华医学会病理学分会消化病学组, 中华医学会外科学分会肝脏外科学组, 中国抗癌协会临床肿瘤学协作专业委员会, 全国肝胆肿瘤及移植病理协作组. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3): 145-151.
[8] Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imrecist): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol, 2018, 36(9): 850-858.
[9] Huang B, Lei S, Wang D, et al. Sulforaphane exerts anticancer effects on human liver cancer cells via induction of apoptosis and inhibition of migration and invasion by targeting mapk7 signalling pathway. J BUON, 2020, 25(2): 959-964.
[10] Kim J, Lee S, Na K. Glycyrrhetinic acid-modified silicon phthalocyanine for liver cancer-targeted photodynamic therapy. Biomacromolecules, 2021, 22(2): 811-822.
[11] 王婵, 沈长清, 吴晓琼, 等. 表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析. 实用肝脏病杂志, 2022, 25(2): 259-262.
[12] Cao X, Wang B. Targeted pd-l1 plga/liposomes-mediated luteolin therapy for effective liver cancer cell treatment. J Biomater Appl, 2021, 36(5): 843-850.
[13] Tu L, Fan Z, Zhu F, et al. Self-recognizing and stimulus-responsive carrier-free metal-coordinated nanotheranostics for magnetic resonance/photoacoustic/fluorescence imaging-guided synergistic photo-chemotherapy. J Mater Chem B, 2020, 8(26): 5667-5681.
[14] Das D, Fayazzadeh E, Li X, et al. Quiescent hepatic stellate cells induce toxicity and sensitivity to doxorubicin in cancer cells through a caspase-independent cell death pathway: central role of apoptosis-inducing factor. J Cell Physiol, 2020, 235(9): 6167-6182.
[15] Wu ZC, Hui XG, Huo L, et al. Antiproliferative effects of isoalantolactone in human liver cancer cells are mediated through caspase-dependent apoptosis, ros generation, suppression of cell migration and invasion and targeting ras/raf/mek signalling pathway. Acta Biochim Pol, 2022, 69(2): 299-304.
[16] Jin B, Liu J, Gao D, et al. Detailed studies on the anticancer action of rosmarinic acid in human hep-g2 liver carcinoma cells: evaluating its effects on cellular apoptosis, caspase activation and suppression of cell migration and invasion. J BUON, 2020, 25(3): 1383-1389.
[17] Yang T, Niu D, Chen J, et al. Biodegradable organosilica magnetic micelles for magnetically targeted MRI and gsh-triggered tumor chemotherapy. Biomater Sci, 2019, 7(7): 2951-2960.
[18] Xu F, Zhu J, Lin L, et al. Multifunctional pvcl nanogels with redox-responsiveness enable enhanced mr imaging and ultrasound-promoted tumor chemotherapy. Theranostics, 2020, 10(10): 4349-4358.
[19] Jie L, Lang D, Kang X, et al. Superparamagnetic iron oxide nanoparticles/doxorubicin-loaded starch-octanoic micelles for targeted tumor therapy. J Nanosci Nanotechnol, 2019, 19(9): 5456-5462.
[20] Xiang Z, Jiang G, Fan D, et al. Drug-internalized bacterial swimmers for magnetically manipulable tumor-targeted drug delivery. Nanoscale, 2020, 12(25): 13513-13522.

微波消融术前阿霉素磁液靶向化疗治疗原发性肝癌患者疗效研究^*

Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邓玉婷, 周俊英. 布加综合征诊治研究进展[J]. 实用肝脏病杂志, 2023, 26(2): 156-159.
[2]	尹雯, 鲁科翔, 王雪, 王彩艳. 恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 173-176.
[3]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[4]	张龙玉, 牟丹蕾, 李侗曾, 张佳莹, 梁连春. 粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 210-213.
[5]	凌佳慧, 倪美鑫, 韩黎黎, 卫栋萍, 戴轶伟, 陈婷婷. 异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2023, 26(2): 214-217.
[6]	李艳芬, 张晓文, 王艳茹, 齐慧芳, 支姗. 应用奥贝胆酸和贝特类药物治疗对熊去氧胆酸治疗不完全应答的原发性胆汁性胆管炎患者临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 226-229.
[7]	徐菁, 刘坤, 马竹芳. 异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 234-237.
[8]	程洋, 张峰, 王曦旋, 尹晓春, 肖江强, 张明, 王雷, 邹晓平, 诸葛宇征. 普萘洛尔与卡维地洛预防肝硬化患者并发食管胃静脉曲张破裂出血临床疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 254-257.
[9]	张斌, 赵宇亮, 闫国贝. hUCB-MNCs联合hUC-MSCs静脉输注治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 262-265.
[10]	周秋娟, 朱逸明, 马宇航, 陈婷闪. TIPS与PSE术治疗乙型肝炎肝硬化并发脾功能亢进症患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 266-269.
[11]	顾凯, 吴晓晨, 朱逸明. 单次大剂量肝区放射照射治疗原发性肝癌肝区疼痛患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 270-273.
[12]	龚程, 田银生, 刘爽. 不同时间窗手术治疗原发性肝癌自发破裂出血患者2年生存率比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 274-277.
[13]	尹秋实, 王学国, 宋奇锋. 左肝蒂阻断法行完全腹腔镜左半肝切除术与开腹手术治疗肝内外胆管结石患者效果比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 282-285.
[14]	黄姝伦, 贺胜铎, 徐小元, 王化虹. 部分肠内营养联合奥曲肽治疗肝硬化乳糜性腹水1例报告[J]. 实用肝脏病杂志, 2023, 26(2): 290-292.
[15]	黄晓铨, 陈世耀. 重视规范化处理门静脉高压并发食管胃静脉曲张出血^*[J]. 实用肝脏病杂志, 2023, 26(1): 1-3.